Shanghai Henlius Biotech, Inc. (2696) entered a partial termination agreement with PT Kalbe Genexine Biologics (KGBio), withdrawing exclusive license rights for the anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab injection) in multiple regions except Indonesia. Under this arrangement, KGBio will transfer the product’s marketing authorisations in the terminated territories to a third party designated by Shanghai Henlius Biotech, Inc., which will make milestone payments of up to US$33.75 million to KGBio.

On the same day, amendments were made to the license agreement with Abbott Products Operations AG (Abbott). Under the revised terms, Abbott will commercialise HANSIZHUANG in 42 additional countries and regions across Asia, the Middle East, Africa, and Eastern Europe. The expanded license includes regulatory milestone payments of not more than US$46.00 million and commercial sales milestone payments of not more than US$80.00 million. The partnership aims to accelerate international market penetration and broaden recognition of HANSIZHUANG in these newly included regions.

HANSIZHUANG has already gained approvals in markets including the Chinese Mainland and various international regions for indications such as lung and esophageal cancers. According to IQVIA MIDASTM, global sales of monoclonal antibody drugs targeting PD-1 amounted to US$45.70 billion in 2024, underscoring the growing market potential for HANSIZHUANG worldwide.